Dinotefuran + Pyriproxyfen + Permethrin

Verify with FDA CVM →

214 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
214
Total Reports
8
Deaths Reported
370.0%
Death Rate

Active Ingredients

Dinotefuran + Pyriproxyfen + Permethrin

Administration Routes

TopicalUnknownOralCutaneousAuricular (Otic)

Species Affected

Dog 213
Cat 1

Most Affected Breeds

Retriever - Labrador 35
Retriever - Golden 16
Shepherd Dog - German 13
Crossbred Canine/dog 13
Shih Tzu 9
Dachshund (unspecified) 8
Shepherd Dog - Australian 7
Terrier - Yorkshire 7
Beagle 6
Terrier (unspecified) 6

Most Reported Reactions

Vomiting 46
Lack of efficacy (endoparasite) - heartworm 33
Lethargy (see also Central nervous system depression in 'Neurological') 28
Diarrhoea 22
Other abnormal test result NOS 16
Lack of efficacy (endoparasite) - hookworm 15
Not eating 13
Lack of efficacy (bacteria) - Borrelia 13
Lack of efficacy - NOS 12
Emesis 11
Behavioural disorder NOS 9
Seizure NOS 8

Outcome Breakdown

Outcome Unknown
116 (54.2%)
Recovered/Normal
57 (26.6%)
Ongoing
31 (14.5%)
Euthanized
6 (2.8%)
Recovered with Sequela
2 (0.9%)
Died
2 (0.9%)

Data Summary

Metric Value
Total adverse event reports 214
Reports involving death 8
Case-fatality rate (reported events) 370.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dinotefuran + Pyriproxyfen + Permethrin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 214 adverse event reports referencing Dinotefuran + Pyriproxyfen + Permethrin, including 8 reports in which the animal died — a 370.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dinotefuran + Pyriproxyfen + Permethrin. Reported administration routes include Topical, Unknown, Oral, Cutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dinotefuran + Pyriproxyfen + Permethrin reports are Dog (213 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (35), Retriever - Golden (16), Shepherd Dog - German (13) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dinotefuran + Pyriproxyfen + Permethrin are Vomiting (46), Lack of efficacy (endoparasite) - heartworm (33), Lethargy (see also Central nervous system depression in 'Neurological') (28), Diarrhoea (22). Of the 214 reports with a coded outcome, Outcome Unknown is the leading category at 54.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dinotefuran + Pyriproxyfen + Permethrin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial